The acquisition of Solexa by Illumina involved strategic financial decisions and a combination of technology strengths to create a successful sequencing platform.
There were missed opportunities and challenges due to financial constraints and differing viewpoints among key players in the sequencing technology industry.
The early 2000s marked a period of significant innovation and the emergence of next-generation sequencing technologies, with various companies maneuvering to establish themselves in the market.
PPMSeq is a duplex sequencing technique that ensures high accuracy reads by reading both forward and reverse strands of a double-stranded sequence.
Ultima's PPMSeq works by amplifying both strands on the same bead and utilizing a tag to identify their presence, with errors causing radical dephasing which is taken care of by downstream software.
Approaches to implementing PPMSeq on Ultima's platform involve reading both strands in both directions simultaneously or keeping the product on beads in the same orientation, each with its own challenges and considerations.
PacBio faced challenges in the stock market but still aims to provide high-quality clinical genomic sequencing. They are seen as a strong competitor in the long-read space despite financial struggles.
Oxford Nanopore has been active in raising funds but has dealt with internal issues and departures of significant team members. Profitability remains an elusive goal for both them and PacBio.
New competitors are emerging in the long-read sequencing market, including Roche and BGI, who are exploring nanopore sequencing technology. This could shake up the landscape for current players.
PacBio's market cap drops below $1B, making it potentially attractive for acquisition.
Despite some positives like new instruments and competitive specs, PacBio faces challenges in gaining traction for long-read sequencing in clinical settings.
The majority of PacBio's IP expires in 2029, raising concerns that competitors could enter the market in the near future.
Protein sequencing can potentially be easier than expected with nanopore technology, allowing for detection of PTMs and obtaining unique fingerprints from proteins.
Proteomics differs from DNA sequencing in that it allows for estimating protein abundance and identifying PTMs in samples, possibly through aligning multiple protein traces.
Challenges in proteomics applications with nanopore platforms include achieving the necessary dynamic range for accurate measurements, which may require advancements in technology.
Universal Sequencing Technology is gaining attention again after being quiet for a while. People are curious about their progress and what they are focusing on now.
They seem to have shifted their focus from single molecule sequencing to developing various sample preparation kits. This shows they are adapting to changes in the field.
This update may be particularly interesting for those who follow advancements in sequencing technology and want to know about new tools or methods in the industry.
The old Roswell company appears to be rebooting as SemiConBio with a new CEO (Mike Aicher) and a small team still active, which is surprising given expectations they were out of cash.
Recent successful demonstrations of DNA expansion by companies like Roche could lower the technical bar for solid‑state readout technologies, making such sensors more attractive as alternatives to bilayer nanopores.
SemiConBio’s specific sequencing approach probably isn’t a direct fit for reading expanded DNA, but some of its components or techniques might be repurposed to build a high‑speed, solid‑state readout.